Table 1.

Human young adult cutaneous microvascular clinical outcomes with cutaneous Tempol (TP).

Reference	Cohort	Presenting	Results	Comments
Fujii et al., 2014	Young adult age current chronic smokers of cigarette tobacco	Impaired microvascular function associated with current chronic cigarette smoking	In 90% of subjects, cutaneous TP administration restored plateau Cutaneous Vascular Conductance, CVC1, compared to control non-treated (no TP) cigarette tobacco smokers	TP restores cutaneous microvascular function and Nitric Oxide and Nitric Oxide Synthetase dependent vasodilation
Medow et al., 2011	Young adult age non-smokers (not a cigarette smoker and not exposed to secondhand cigarette smoke)	Healthy; no impaired microvascular function	In 100%, of subjects, cutaneous TP administration had no effect on plateau CVC, compared to controls in young adult non-smokers	Cohort not expected to have high amounts of Reactive Oxygen Species (ROS) and not expected to have impaired microvascular function
Medow et al., 2011	Young adult age non-smokers with oxidative stress experimentally induced by infusion of angiotensin II	Impaired microvascular dysfunction induced by angiotensin II	In 90% of subjects, cutaneous TP administration restored plateau CVC when Reactive Oxygen Species (ROS) was induced by angiotensin II	TP restores microvascular function by inhibiting ROS

¹Cutaneous Vascular Conductance (CVC) as evaluated by cutaneous red blood cell flux divided by the mean arterial blood pressure (MAP).